OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells , or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in ... (more)
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130603005565&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20130603005565&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment